19 January 2024 in Meditsinskiy sovet = Medical Council
Introduction. The development and study of new enteral nutrition (EN) formulas is a major challenge to modern practical medicine. The creation of enteral nutrition products, which in addition to their intrinsic nutritional properties have detoxifying properties, will contribute to enhanced clinical efficacy and more active recovery of patients.Aim. To conduct a comparative pharmaco-economic analysis of the effectiveness of using new domestic products for enteral nutrition produced by LEOVIT Nutrio (Russia), which have detoxifying activity, and products from other manufacturers.Materials and methods. The studies were carried out using standard cost-effectiveness analysis techniques. A comparative analysis of following products:Nutrien Standard (JSC Infaprim, Russia), Supportan drink (FreseniusKabi, Germany), Nutridrink compact protein (Nutricia, Holland) and Peptamen (Nestle, Switzerland), Detoxifying Protein Cocktail, Restoring Protein Cocktail and Detoxifying Drink (LEOVIT Nutrio LLC, Russia).Results and discussion. Calculations for all analyzed economic parameters showed the advantages of using new domestic products for enteral nutrition. It was found that the total direct costs for enteral nutrition in the group of cancer patients who additionally took a detoxification cocktail were the smallest and amounted to 3332.0 rub, the increase in blood protein concentration over 14 days of therapy was 11.1 g/l, and for albumin over the indicated period is 6.7 g/l. Compared to products from other manufacturers, the lowest cost in relation to the achieved effect (CER) was observed when using a restorative cocktail – 305.69 rub. for protein and 512.62 rub. by albumin. The total direct costs for enteral nutrition in the group of patients who took the Detoxification Drink in comparison with other products on the Russian market were also the lowest and amounted to 840.00 rubles.Conclusions. The authors concluded that there are significant economic advantages of using the new domestic enteral nutrition LEOVIT compared to other products and consider them as the product of choice when providing enteral protein nutrition to patients with various diseases accompanied by intoxication of the organism.
12 March 2022 in Meditsinskiy sovet = Medical Council
This review presents current data on immunopathogenesis, the role of cytokines in inflammation in atopic dermatitis (AD). The pathogenetic phenotypes of the disease associated with various abnormalities of immune mechanisms and dysfunction of the epidermal barrier are considered. The inflammatory processes in atopic dermatitis were shown to be implemented mainly through Th2-lymphocytes and IL-4 and IL-13 produced by these cells, which play a key role in the allergic cascade. It is the effects of IL-4 and IL-13 cytokines that determine the main pathophysiological mechanisms, such as decreased expression of epidermal barrier proteins and suppression of terminal differentiation of keratinocytes, microbiota disturbances, tissue remodelling, immunoglobulin isotype switching by B-lymphocytes and IgE synthesis, degranulation of mast cells and basophils, trafficking of inflammatory cells into tissues, itching. Moderate and severe forms of AD require administration of systemic therapy, which has been represented until recently by non-selective immunosuppressive drugs with moderate efficacy and pronounced side effects if they are used for a long time. Modern targeted therapy of atopic dermatitis provides for the use of monoclonal antibodies against both pro-inflammatory cytokines and their receptors. Directional action on the key mechanisms and targets of immune inflammation can minimize possible side effects of immunosuppressive therapy. Clinical trials on the efficacy and safety of IL-4 and IL-13 inhibitors in the treatment of atopic dermatitis are described.
11 March 2022 in Meditsinskiy sovet = Medical Council
Hand eczema is a common multi-etiological disease manifested by evolutionary polymorphism of rashes. Hand eczema develops against the background of altered reactivity and genetic predisposition under the adverse effects of endogenous and exogenous factors. Hand eczema has a chronic course and is characterized by a wide range of clinical manifestations. The prevalence of eczematous lesions of the hands among the adult population is 1–2%, and among all skin diseases – 30–40%. The disease has an extremely negative impact on the quality of life, ability to work, career prospects and the social status of a person. The long course of eczematous lesions of the hands can be complicated by a secondary infection: bacterial and mycotic flora. Therefore, choosing the right and effective treatment for hand eczema is a particularly difficult task for a dermatologist. In recent years, a multicomponent drug based on gentamicin sulfate, dexpanthenol, mometasone furoate and econazole nitrate has been widely used for the treatment of hand eczema due to its high efficacy, tolerability, and safety. The use of this multicomponent drug in monotherapy for hand eczema is effective, leads to clinical remission and restoration of the quality of life of patients and is not accompanied by side effects and complications. This review focuses on the epidemiology, clinical features, and treatment options for hand eczema. Clinical experience with the use of a multicomponent drug in patients with hand eczema complicated by infection is also given.
7 October 2020 in Meditsinskiy sovet = Medical Council
Introduction. The article provides latest data on modern methods of treating rosacea. The results of own clinical observations of patients with moderate to severe papulopustular rosacea receiving combination treatment and a comparative analysis of the efficacy of various therapy regimens are presented.Objective of the study. The aim of the study was to conduct a comparative analysis of the therapeutic efficacy of combination therapy using the ivermectin 1% topical drug combined with systemic therapy drugs (doxycycline, minocycline, isotretinoin).Materials and methods. We observed 37 patients with moderate to severe papulo-pustular rosacea subtype. The patients were divided into 4 groups (A, B, C, D). Patients in the control group received monotherapy with 1% ivemectin topical drug, patients in the other groups received combination therapy (1% ivermectin combined with low-dose doxycycline, minocycline and isotretinoin). The efficacy of the therapy was evaluated by measuring rosacea severity on the Scale for Diagnostic Assessment of Rosacea (SDAR), clinical manifestations according to the IGA (Investigator Global Assessment) criteria, and by assessing the patients' quality of life using the DLQI (Dermatology Life Quality Index) questionnaire before and after 3-month treatment.Results. The comparative analysis of changes in severity indicators of the skin process and quality of life in patients with moderate to severe papulopustular rosacea after topical and combination therapy showed that the results of the treatment in patients receiving combination therapy were more significant than those in the group receiving monotherapy.Conclusion. The concomitant use of 1% ivermectin and systemic drugs is most effective in patients with severe papulopustular rosacea subtype. The combination treatment tailored to the clinical forms and severity of rosacea allows to optimize the clinical results of the therapy, which significantly affects the patients' quality of life and opens up potential for an individual approach in the algorithms for the treatment of rosacea.
16 June 2024 in Russian Journal of Allergy
BACKGROUND: Association of alopecia areata and atopic diseases has been confirmed in clinical, epidemiologic, genetic and immunologic studies. The study of sensitization features and atopic diseases structure in alopecia areata patients makes it possible to phenotype patients with atopy and consider additional treatment options for alopecia areata. AIM: To determine the sensitization spectrum and atopic diseases structure in alopecia areata patients considering the age and clinical form of alopecia. MATERIALS AND METHODS: A comparative uncontrolled study was conducted. The data of 162 patients 5–51 years with alopecia areata, atopic dermatitis, asthma, allergic rhinitis/rhinoconjuctivitis for the period from April 2022 to May 2023 were used. The nature of sensitization and the structure of atopic diseases were analyzed. Clinical forms of alopecia areata were assessed by the hair-loss area. RESULTS: The patients were divided according to alopecia areata status: the first group included 54 alopecia areata patients with atopic diseases, the second ― 108 atopic patients without alopecia areata. Subgroups were formed according to age: in group 1 the mean age was 16.3±1.38 years, 57% were children (5–17 years), 43% were older 18 years; in group 2 the mean age was 17.1±1.43 years, 54% children and 46% adults. Among alopecia areata patients seasonal pollen sensitization prevailed (22/54 people); polyvalent sensitization was observed in 13/54 people, 6 of whom had severe forms of alopecia areata, 6 ― ophiasis. Comparison of the sensitization spectrum between the groups revealed no differences. In group of adult alopecia areata patients isolated respiratory allergies were significantly less frequent (OR 0.21; CI 0.07–0.60; p=0.004), but combined atopic diseases were more frequently observed (OR 4.71; CI 1.43–15.58; p=0.012). Most patients with severe alopecia areata were children (8/12) with polyvalent sensitization and respiratory and combined atopic diseases. CONCLUSION: The comorbidity of alopecia areata and atopy is manifested by an increased incidence of severe alopecia in childhood and a tendency to progression of allergic inflammation, realized as combined atopic diseases. The spectrum of sensitization in patients with and without alopecia areata does not differ and characterized by the predominance of the most common allergens (plant pollen). These results indicate the need for timely phenotyping of alopecia areata patients with allergic predisposition, especially with early onset and progressive alopecia.
7 March 2024 in Meditsinskiy sovet = Medical Council
Post-inflammatory hyperpigmentation (PIH) is one of the most significant problems in patients with acne. The prevalence of PIH among patients with acne varies from 45 to 87%. Post-acne, including PIH, has an extremely negative impact on the quality of life and psychological well-being of patients, as it is often resistant to therapy and can persist for even several years. Successful acne treatment does not guarantee complete elimination of PIH and other post-acne symptoms. In the development of PIH, a key role is played by the mechanism associated with the production and distribution of melanin, which is activated by inflammation and the release of cytokines that promote an increase in the level of immunoreactive tyrosinase, which stimulates melanocytes, activation of melanogenesis and further transfer of melanosomes to surrounding keratinocytes. It is important for clinicians to recognize the psychosocial impact of PIH and manage inflammation, as well as proactively address residual PIH with appropriate treatment. Thus, prevention and correction of PIH should be one of the goals of acne treatment. Topical therapy for PIH in acne is considered the most acceptable and can be prescribed both as monotherapy and as part of combined methods. Tyrosinase is a target for topical anti-pigmentation agents, including hydroquinone, kojic acid, and resorcinyl thiazole derivatives. The latter includes isobutylamidothiazolyl resorcinol – thiamidol. The article provides a brief overview of data on the epidemiology of PIH, its pathogenesis, impact on the quality of life of patients and the perception of their image by people around them. Clinical experience with the use of anti-hyperpigmentation serum with thiamidol, licochalcone A and sodium hyaluronate is presented, which confirms the effectiveness, safety and feasibility of prescribing products with thiamidol for the treatment of PIH caused by acne.